Sepset Biosciences Inc.

Sepset Biosciences is a diagnostic company in advanced development of a blood test (Sepset-ER) for hospitals to identify patients in the emergency room (ER) who will acquire severe sepsis and have high risk for organ failure. Sepset’s test will provide much earlier (~1-2 hours) and more reliable data to help physicians select the right treatment for the right patients at the right time. This is critical since every hour’s delay in starting appropriate treatment leads to a 7.6% increased risk of death (Kumar, 2006). At the same time the Sepset-ER test will inform physicians who will not acquire sepsis, sparing the need to use potent antibiotics and increase the risk of antimicrobial resistance. Our vision is to increase patient survival and improve quality of care, while at the same time improving efficiency in hospital spending.